Incyte - INCY Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $75.50
Forecasted Upside: 49.15%
Number of Analysts: 16
Breakdown:
0 Sell Ratings
9 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$50.62 As of 04/25/2024 11:10 AM ET

▼ -1.12 (-2.16%)

1 month | 3 months | 12 months

Get New Incyte Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for INCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INCY

^$75.50

▲ +49.15% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $75.50, with a high forecast of $93.00 and a low forecast of $64.00. The average price target represents a 49.15% upside from the last price of $50.62.

Current Consensus is Hold

The current consensus among 16 polled investment analysts is to hold stock in Incyte. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

11/2/2022

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

1/31/2023

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

5/1/2023

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

7/30/2023

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

10/28/2023

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

1/26/2024

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

3/26/2024

0 strong buy ratings
7 buy ratings
9 hold ratings
0 sell ratings

Ratings as of

4/25/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/24/2024	Oppenheimer	Lower Target	Outperform ➝ Outperform	$92.00 ➝ $84.00	Low
4/23/2024	Cantor Fitzgerald	Initiated Coverage	Neutral		Low
3/25/2024	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$65.00	Low
3/13/2024	Bank of America	Lower Target	Neutral ➝ Neutral	$69.00 ➝ $67.00	Low
2/23/2024	Jefferies Financial Group	Initiated Coverage	Buy	$81.00	Low
2/14/2024	BMO Capital Markets	Boost Target	Market Perform ➝ Market Perform	$58.00 ➝ $64.00	Low
2/14/2024	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$63.00 ➝ $65.00	Low
2/14/2024	Citigroup	Lower Target	Buy ➝ Buy	$82.00 ➝ $81.00	Low
2/14/2024	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$67.00 ➝ $68.00	Low
2/14/2024	Truist Financial	Lower Target	Buy ➝ Buy	$91.00 ➝ $84.00	Low
2/14/2024	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low
2/6/2024	William Blair	Reiterated Rating	Outperform		Low
12/14/2023	Mizuho	Lower Target	Neutral ➝ Neutral	$82.00 ➝ $77.00	Low
12/13/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$93.00	Low
12/13/2023	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$78.00	Low
12/4/2023	Guggenheim	Upgrade	Neutral ➝ Buy	$86.00	Low
11/29/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$91.00	Low
11/21/2023	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$98.00 ➝ $65.00	Low
11/2/2023	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$114.00 ➝ $98.00	Low
11/1/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$74.00 ➝ $63.00	Low
11/1/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$74.00 ➝ $64.00	Low
9/21/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$91.00	Low
8/2/2023	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$92.00	Low
8/2/2023	BMO Capital Markets	Lower Target	Market Perform ➝ Market Perform	$70.00 ➝ $68.00	Low
8/2/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$93.00	Low
8/2/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$74.00	N/A
8/2/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$70.00 ➝ $73.00	N/A
8/2/2023	Stifel Nicolaus	Boost Target	Hold ➝ Hold	$73.00 ➝ $76.00	Low
8/2/2023	Truist Financial	Lower Target	Buy ➝ Buy	$100.00 ➝ $91.00	Low
7/25/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$93.00	Low
7/25/2023	Citigroup	Initiated Coverage	Buy	$82.00	Low
7/20/2023	Morgan Stanley	Reiterated Rating	Underweight ➝ Underweight	$74.00	Low
5/4/2023	JMP Securities	Lower Target		$113.00 ➝ $93.00	Low
5/4/2023	Bank of America	Downgrade	Buy ➝ Neutral	$84.00	Low
5/3/2023	VNET Group	Reiterated Rating	Maintains		Low
5/3/2023	BMO Capital Markets	Lower Target		$75.00 ➝ $70.00	Low
5/3/2023	Royal Bank of Canada	Lower Target		$79.00 ➝ $70.00	Low
5/3/2023	Stifel Nicolaus	Lower Target		$80.00 ➝ $73.00	Low
5/3/2023	Mizuho	Lower Target		$95.00 ➝ $82.00	Low
4/19/2023	JMP Securities	Reiterated Rating	Market Outperform	$113.00	Low
4/12/2023	Morgan Stanley	Boost Target	Equal Weight	$76.00 ➝ $77.00	Low
4/10/2023	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$81.00 ➝ $79.00	Low
3/28/2023	JMP Securities	Reiterated Rating	Market Outperform	$113.00	Low
3/24/2023	SVB Securities	Upgrade	Underperform ➝ Market Perform	$61.00	Low
3/20/2023	William Blair	Reiterated Rating	Outperform		Low
3/7/2023	JMP Securities	Reiterated Rating	Buy	$113.00	Low
2/16/2023	Credit Suisse Group	Boost Target	Buy	$95.00 ➝ $100.00	Low
2/13/2023	JMP Securities	Reiterated Rating	Market Outperform	$113.00	Low
2/8/2023	Piper Sandler	Reiterated Rating	Overweight	$100.00	Low
2/8/2023	Mizuho	Reiterated Rating	Neutral	$95.00	Low
2/8/2023	JPMorgan Chase & Co.	Lower Target	Neutral	$82.00 ➝ $80.00	Low
2/8/2023	SVB Leerink	Reiterated Rating	Underperform	$63.00	Low
2/8/2023	Cowen	Boost Target	Outperform	$95.00 ➝ $100.00	Low
1/31/2023	Piper Sandler	Initiated Coverage	Overweight	$100.00	Low
1/3/2023	Wells Fargo & Company	Boost Target	Equal Weight	$72.00 ➝ $75.00	Low
11/2/2022	Morgan Stanley	Boost Target	Equal Weight	$76.00 ➝ $77.00	Low
11/2/2022	Royal Bank of Canada	Boost Target	Outperform	$77.00 ➝ $82.00	Low
10/24/2022	JPMorgan Chase & Co.	Lower Target	Neutral	$86.00 ➝ $80.00	Low
10/18/2022	Wells Fargo & Company	Lower Target	Equal Weight	$76.00 ➝ $75.00	Low
9/22/2022	Evercore ISI	Downgrade	In-Line		Low
8/9/2022	Guggenheim	Downgrade	Neutral		Low
8/3/2022	Morgan Stanley	Lower Target	Equal Weight	$77.00 ➝ $76.00	N/A
8/3/2022	Evercore ISI	Downgrade	Outperform ➝ Inline	$90.00 ➝ $78.00	Low
8/3/2022	Oppenheimer	Lower Target		$109.00 ➝ $98.00	Low
8/3/2022	Guggenheim	Downgrade	Buy ➝ Neutral		Low
7/28/2022	Wells Fargo & Company	Initiated Coverage	Equal Weight	$76.00	Low
7/20/2022	SVB Leerink	Boost Target	Underperform	$58.00 ➝ $63.00	Low
5/3/2022	Stifel Nicolaus	Boost Target		$75.00 ➝ $77.00	Low
4/20/2022	Morgan Stanley	Boost Target	Equal Weight	$73.00 ➝ $76.00	Low
2/9/2022	SVB Leerink	Downgrade	Market Perform ➝ Underperform	$60.00 ➝ $56.00	Low
2/2/2022	Morgan Stanley	Lower Target	Equal Weight	$77.00 ➝ $76.00	Low
1/18/2022	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$78.00 ➝ $90.00	Medium
1/3/2022	Guggenheim	Lower Target		$118.00 ➝ $104.00	High
12/17/2021	JMP Securities	Reiterated Rating	Buy	$108.00	High
11/18/2021	BMO Capital Markets	Initiated Coverage	Market Perform	$75.00	Low
11/4/2021	JMP Securities	Lower Target	Market Outperform	$124.00 ➝ $108.00	High
11/3/2021	Oppenheimer	Lower Target	Outperform	$110.00 ➝ $109.00	High
10/15/2021	Cantor Fitzgerald	Lower Target	Neutral	$104.00 ➝ $79.00	Low
10/4/2021	Truist Financial	Lower Target	Buy	$120.00 ➝ $95.00	Medium
9/24/2021	JMP Securities	Reiterated Rating	Buy	$124.00	Low
9/23/2021	Morgan Stanley	Lower Target	Equal Weight	$85.00 ➝ $80.00	Low
9/23/2021	Royal Bank of Canada	Lower Target	Sector Perform	$91.00 ➝ $86.00	Low
8/4/2021	SVB Leerink	Lower Target	Underperform	$70.00 ➝ $67.00	Low
7/20/2021	Benchmark	Upgrade	Hold ➝ Buy	$89.00	Medium
6/25/2021	Royal Bank of Canada	Lower Target	Sector Perform	$92.00 ➝ $88.00	Low
6/15/2021	William Blair	Reiterated Rating	Outperform		Low
6/15/2021	SVB Leerink	Reiterated Rating	Sell		Low
5/5/2021	Morgan Stanley	Lower Target	Equal Weight	$86.00 ➝ $85.00	Low
4/5/2021	Morgan Stanley	Lower Target	Equal Weight	$93.00 ➝ $86.00	Low
2/10/2021	Morgan Stanley	Lower Target	Equal Weight	$97.00 ➝ $93.00	Low
2/10/2021	SVB Leerink	Downgrade	Market Perform ➝ Underperform	$89.00 ➝ $70.00	Low
1/7/2021	Truist Financial	Initiated Coverage	Buy	$120.00	N/A
1/4/2021	Guggenheim	Upgrade	Neutral ➝ Buy		N/A
11/9/2020	Morgan Stanley	Lower Target	Equal Weight	$103.00 ➝ $97.00	High
11/6/2020	BMO Capital Markets	Lower Target	Market Perform	$94.00 ➝ $87.00	Medium
11/6/2020	Royal Bank of Canada	Lower Target	Sector Perform	$96.00 ➝ $86.00	Medium
10/15/2020	Bank of America	Lower Target	Buy	$113.00 ➝ $110.00	Low
10/13/2020	Morgan Stanley	Boost Target	Equal Weight	$100.00 ➝ $103.00	Low
8/9/2020	Cowen	Reiterated Rating	Buy		Medium
8/6/2020	BMO Capital Markets	Boost Target	Market Perform	$90.00 ➝ $94.00	Low
8/6/2020	Credit Suisse Group	Lower Target	Neutral	$100.00 ➝ $97.00	Low
8/6/2020	Morgan Stanley	Boost Target	Equal Weight	$95.00 ➝ $100.00	Low
8/4/2020	Mizuho	Initiated Coverage	Hold	$79.00 ➝ $95.00	Medium
8/4/2020	SVB Leerink	Boost Target	Market Perform	$86.00 ➝ $87.00	Low
8/3/2020	Royal Bank of Canada	Boost Target	Sector Perform	$91.00 ➝ $92.00	High
7/28/2020	JPMorgan Chase & Co.	Reiterated Rating	Hold	$99.00	Low
7/24/2020	William Blair	Reiterated Rating	Buy		Low
7/20/2020	Credit Suisse Group	Boost Target	Neutral	$88.00 ➝ $100.00	High
7/17/2020	Oppenheimer	Reiterated Rating	Buy	$121.00	High
6/17/2020	William Blair	Reiterated Rating	Buy		Low
6/16/2020	Benchmark	Initiated Coverage	Hold		Low
6/15/2020	Oppenheimer	Initiated Coverage	Buy	$120.00	Medium
6/4/2020	Argus	Boost Target	Buy	$92.00 ➝ $124.00	High
5/26/2020	The Goldman Sachs Group	Downgrade	Conviction-Buy ➝ Buy		High
5/19/2020	Cantor Fitzgerald	Boost Target	Neutral	$83.00 ➝ $100.00	Medium
5/12/2020	Morgan Stanley	Boost Target	Equal Weight	$94.00 ➝ $95.00	High
5/6/2020	Credit Suisse Group	Reiterated Rating	Hold	$88.00	Low
5/6/2020	BMO Capital Markets	Boost Target	Market Perform	$74.00 ➝ $90.00	Low
5/6/2020	Nomura	Reiterated Rating	Buy	$116.00	Low
5/6/2020	Oppenheimer	Boost Target	Outperform	$112.00 ➝ $120.00	Medium
5/6/2020	Royal Bank of Canada	Boost Target	In-Line ➝ Sector Perform	$81.00 ➝ $91.00	Medium
5/5/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$89.00 ➝ $99.00	Medium
4/29/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$94.00	Medium
4/21/2020	Oppenheimer	Boost Target	Outperform	$90.00 ➝ $112.00	Medium
4/20/2020	Piper Sandler	Boost Target	Overweight	$95.00 ➝ $110.00	Low
4/19/2020	Mizuho	Reiterated Rating	Hold	$79.00	Low
4/9/2020	William Blair	Reiterated Rating	Buy		Low
4/8/2020	Royal Bank of Canada	Reiterated Rating	Hold	$81.00	Medium
4/8/2020	Nomura Securities	Reiterated Rating	Buy	$116.00	Medium
4/7/2020	Oppenheimer	Boost Target	Outperform	$85.00 ➝ $90.00	Low
4/6/2020	Piper Sandler	Reiterated Rating	Buy		High
4/1/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$83.00 ➝ $90.00	Medium
3/25/2020	Oppenheimer	Lower Target		$99.00 ➝ $85.00	High
3/24/2020	William Blair	Initiated Coverage	Outperform		High
3/18/2020	Royal Bank of Canada	Reiterated Rating	Hold	$81.00	Medium
3/13/2020	Bank of America	Upgrade	Neutral ➝ Buy	$83.00	High
3/11/2020	Credit Suisse Group	Lower Target	Neutral	$86.00 ➝ $81.00	Medium
2/19/2020	Piper Sandler	Reiterated Rating	Buy		Low
2/19/2020	Nomura Securities	Boost Target	Buy	$111.00 ➝ $116.00	Low
2/19/2020	Cowen	Reiterated Rating	Buy		Low
2/16/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$89.00	Low
2/16/2020	Evercore ISI	Reiterated Rating	Buy	$92.00	Low
2/13/2020	Mizuho	Reiterated Rating	Hold	$79.00	High
2/4/2020	Bank of America	Reiterated Rating	Neutral	$82.00	Low
1/30/2020	Royal Bank of Canada	Reiterated Rating	Hold	$80.00	Medium
1/27/2020	Evercore ISI	Reiterated Rating	Buy	$92.00	Low
1/23/2020	Cantor Fitzgerald	Boost Target	Neutral	$65.00 ➝ $83.00	Low
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
1/14/2020	JMP Securities	Reiterated Rating	Outperform	$121.00	High
1/13/2020	Cowen	Reiterated Rating	Buy		High
1/6/2020	Royal Bank of Canada	Reiterated Rating	Hold ➝ Neutral		High
1/6/2020	Morgan Stanley	Lower Target	Equal Weight	$89.00 ➝ $83.00	Low
1/3/2020	Royal Bank of Canada	Lower Target		$80.00	Medium
1/3/2020	The Goldman Sachs Group	Lower Target	Buy	$122.00 ➝ $107.00	High
1/3/2020	Credit Suisse Group	Lower Target	Neutral	$90.00 ➝ $86.00	High
1/3/2020	Oppenheimer	Lower Target	Outperform	$100.00 ➝ $96.00	High
1/3/2020	BMO Capital Markets	Lower Target	Market Perform	$85.00 ➝ $74.00	High
1/3/2020	Citigroup	Reiterated Rating	Outperform	$100.00 ➝ $96.00	High
1/3/2020	JMP Securities	Lower Target	Market Outperform	$110.00 ➝ $99.00	High
1/3/2020	Cantor Fitzgerald	Lower Target	Neutral	$75.00 ➝ $65.00	High
1/2/2020	Mizuho	Downgrade	Buy ➝ Neutral	$98.00 ➝ $79.00	High
1/2/2020	Piper Sandler Companies	Reiterated Rating	Buy	$95.00	High
1/2/2020	Cowen	Reiterated Rating	Buy		High
1/2/2020	Guggenheim	Downgrade	Buy ➝ Neutral		Medium
12/18/2019	Mizuho	Reiterated Rating	Buy	$98.00	Low
11/27/2019	Mizuho	Reiterated Rating	Buy	$98.00	Low
10/29/2019	Mizuho	Reiterated Rating	Buy	$95.00	Medium
10/2/2019	Mizuho	Initiated Coverage	Buy	$95.00	Medium
9/30/2019	JMP Securities	Boost Target	Buy ➝ Market Outperform	$107.00 ➝ $110.00	Medium
9/27/2019	Cowen	Reiterated Rating	Buy		Low
9/27/2019	Guggenheim	Set Target	Buy	$101.00	Low
9/12/2019	BMO Capital Markets	Initiated Coverage	Market Perform	$85.00	High
9/5/2019	Morgan Stanley	Boost Target	Equal ➝ Equal Weight	$82.00 ➝ $87.00	High
9/5/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$85.00 ➝ $100.00	Medium
9/5/2019	JMP Securities	Upgrade	Market Perform ➝ Outperform	$107.00	Medium
8/4/2019	Cowen	Reiterated Rating	Buy		Low
7/31/2019	SVB Leerink	Set Target	Hold	$90.00	Medium
7/31/2019	Nomura Securities	Boost Target	Buy	$100.00 ➝ $111.00	Low
7/31/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$91.00	Low
7/31/2019	Morgan Stanley	Boost Target	Equal Weight	$81.00 ➝ $82.00	Low
6/17/2019	Piper Sandler Companies	Reiterated Rating	Buy		Low
5/27/2019	Cowen	Reiterated Rating	Buy		Low
5/20/2019	Credit Suisse Group	Initiated Coverage	Neutral	$75.00	Medium
5/15/2019	Piper Sandler Companies	Boost Target	Overweight	$85.00 ➝ $95.00	Low
5/15/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$90.00	Low
5/3/2019	Barclays	Downgrade	Overweight ➝ Equal Weight	$90.00 ➝ $82.00	High
4/30/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		High

(Data available from 4/25/2019 forward)

News Sentiment Rating

0.77 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

13 very positive mentions
7 positive mentions
1 negative mentions
3 very negative mentions

Mentions as of

9/28/2023

10 very positive mentions
13 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

10/28/2023

5 very positive mentions
23 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

11/27/2023

19 very positive mentions
7 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/27/2023

17 very positive mentions
25 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

1/26/2024

30 very positive mentions
33 positive mentions
5 negative mentions
2 very negative mentions

Mentions as of

2/25/2024

24 very positive mentions
20 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/26/2024

15 very positive mentions
17 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

4/25/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $50.62

$50.60

$51.85

50 Day Range

MA: $57.06

$51.65

$61.00

52 Week Range

Now: $50.62

$50.27

$75.74

Volume

194,796 shs

Average Volume

1,704,429 shs

Market Capitalization

$11.37 billion

P/E Ratio

19.10

Dividend Yield

N/A

Beta

0.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?: The following equities research analysts have issued research reports on Incyte in the last twelve months: Bank of America Co., BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Guggenheim, Jefferies Financial Group Inc., JMP Securities, Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Royal Bank of Canada, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist Financial Co., VNET Group, Inc., and William Blair.
View the latest analyst ratings for INCY.
What is the current price target for Incyte?: 14 Wall Street analysts have set twelve-month price targets for Incyte in the last year. Their average twelve-month price target is $75.50, suggesting a possible upside of 45.9%. JMP Securities has the highest price target set, predicting INCY will reach $93.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $64.00 for Incyte in the next year.
View the latest price targets for INCY.
What is the current consensus analyst rating for Incyte?: Incyte currently has 9 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INCY, but not buy more shares or sell existing shares.
View the latest ratings for INCY.
What other companies compete with Incyte?: Other companies that are similar to Incyte include Charles River Laboratories International, PRA Health Sciences, Medpace, Exelixis and PPD. Learn More about companies similar to Incyte.
How do I contact Incyte's investor relations team?: Incyte's physical mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company's listed phone number is (302) 498-6700 and its investor relations email address is [email protected]. The official website for Incyte is www.incyte.com. Learn More about contacing Incyte investor relations.

Incyte - INCY Stock Price Target and Predictions

Analyst Price Target for INCY

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.77 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?

What is the current price target for Incyte?

What is the current consensus analyst rating for Incyte?

What other companies compete with Incyte?

How do I contact Incyte's investor relations team?